诊断学理论与实践

诊断学理论与实践 >

2021 , Vol. 20 >Issue 06: 515 - 521

DOI: https://doi.org/10.16150/j.1671-2870.2021.06.001

专家论坛

造血干细胞移植后非感染性肺部并发症的诊治进展

展开
  • 上海交通大学医学院附属瑞金医院 国家转化医学中心血液科,上海 200025

收稿日期: 2021-11-08

  网络出版日期: 2021-12-25

收起

本文引用格式

许晓倩, 卿恺, 张苏江 . 造血干细胞移植后非感染性肺部并发症的诊治进展[J]. 诊断学理论与实践, 2021 , 20(06) : 515 -521 . DOI: 10.16150/j.1671-2870.2021.06.001

参考文献

[1] Barriga F, Ramírez P, Wietstruck A, et al. Hematopoietic stem cell transplantation: clinical use and perspectives[J]. Biol Res, 2012, 45(3):307-316.
[2] de la Morena MT, Gatti RA. A history of bone marrow transplantation[J]. Hematol Oncol Clin North Am, 2011, 25(1):1-15.
[3] Niederwieser D, Baldomero H, Szer J, et al. Hematopoie-tic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey[J]. Bone Marrow Transplant, 2016, 51(6):778-785.
[4] Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome[J]. Am J Respir Crit Care Med, 2011, 183(9):1262-1279.
[5] Soubani AO, Pandya CM. The spectrum of noninfectious pulmonary complications following hematopoietic stem cell transplantation[J]. Hematol Oncol Stem Cell Ther, 2010, 3(3):143-157.
[6] Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation[J]. Blood, 2003, 102(8):2777-2785.
[7] Cengiz Seval G, Topçuoğlu P, Demirer T. Current approach to non-infectious pulmonary complications of hematopoietic stem cell transplantation[J]. Balkan Med J, 2018, 35(2):131-140.
[8] Thompson J, Yin Z, D′Souza A, et al. Etanercept and corticosteroid therapy for the treatment of late-onset idiopathic pneumonia syndrome[J]. Biol Blood Marrow Transplant, 2017, 23(11):1955-1960.
[9] Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach[J]. Biol Blood Marrow Transplant, 2015, 21(12):2061-2068.
[10] Capizzi SA, Kumar S, Huneke NE, et al. Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2001, 27(12):1299-1303.
[11] Martínez-Cibrian N, Magnano L, Gutiérrez-García G, et al. At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study[J]. Bone Marrow Transplant, 2016, 51(4):593-595.
[12] Bondeelle L, Bergeron A. Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation[J]. Expert Rev Respir Med, 2019, 13(1):105-119.
[13] Chi AK, Soubani AO, White AC, et al. An update on pulmonary complications of hematopoietic stem cell transplantation[J]. Chest, 2013, 144(6):1913-1922.
[14] Ahya VN. Noninfectious acute lung injury syndromes early after hematopoietic stem cell transplantation[J]. Clin Chest Med, 2017, 38(4):595-606.
[15] Zhang Z, Wang C, Peters SG, et al. Epidemiology, risk factors, and outcomes of diffuse alveolar hemorrhage after hematopoietic stem cell transplantation[J]. Chest, 2021, 159(6):2325-2333.
[16] Wenger DS, Triplette M, Crothers K, et al. Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(2):413-420.
[17] Keklik F, Alrawi EB, Cao Q, et al. Diffuse alveolar hemor-rhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics[J]. Haematologica, 2018, 103(12):2109-2115.
[18] Haider S, Durairajan N, Soubani AO. Noninfectious pulmonary complications of haematopoietic stem cell transplantation[J]. Eur Respir Rev, 2020, 29(156):190119.
[19] Nakasone H, Onizuka M, Suzuki N, et al. Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchio-litis obliterans organizing pneumonia after hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2013, 48(10):1317-1323.
[20] Adachi Y, Ozeki K, Ukai S, et al. Patterns of onset and outcome of cryptogenic organizing pneumonia after allogeneic hematopoietic stem cell transplantation[J]. Int J Hematol, 2019, 109(6):700-710.
[21] Shiari A, Nassar M, Soubani AO. Major pulmonary complications following hematopoietic stem cell transplantation: What the pulmonologist needs to know[J]. Respir Med, 2021, 185:106493.
[22] Ueda K, Watadani T, Maeda E, et al. Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT[J]. Bone Marrow Transplant, 2010, 45(12):1719-1727.
[23] Kwok WC, Liang BM, Lui MMS, et al. Rapid versus gradual lung function decline in bronchiolitis obliterans syndrome after haematopoietic stem cell transplantation is associated with survival outcome[J]. Respirology, 2019, 24(5):459-466.
[24] Gazourian L, Rogers AJ, Ibanga R, et al. Factors associa-ted with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation[J]. Am J Hematol, 2014, 89(4):404-409.
[25] Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(4):710-716.
[26] Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation[J]. Blood, 2017, 129(4):448-455.
[27] Astashchanka A, Ryan J, Lin E, et al. Pulmonary Complications in Hematopoietic Stem Cell Transplant Reci-pients-A Clinician Primer[J]. J Clin Med, 2021, 10(15):3227.
[28] Bondeelle L, Gras J, Michonneau D, et al. Pleuroparenchymal fibroelastosis after allogeneic hematopoietic stem cell transplantation[J]. Bone Marrow Transplant, 2020, 55(5):982-986.
[29] Sato S, Hanibuchi M, Takahashi M, et al. A patient with idiopathic pleuroparenchymal fibroelastosis showing a sustained pulmonary function due to treatment with pirfenidone[J]. Intern Med, 2016, 55(5):497-501.
[30] Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J, 2019, 53(1):1801913.
[31] Dandoy CE, Hirsch R, Chima R, et al. Pulmonary hypertension after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2013, 19(11):1546-1556.
Options
文章导航

/

〈 〉